Friday, December 10, 2010

THE WORK-UP: COSTLY DRUGS KNOWN AS BIOLOGICS PROMPT EXCLUSIVITY DEBATE



Companies that own the rights to high-end treatments say allowing copycats to market too soon would hurt financial incentives.

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)